Enanta Pharmaceuticals Inc 8-K, filed Mar 2, 2020
Enanta Pharmaceuticals Inc (ENTA)
About this 8-K
Enanta Pharmaceuticals Inc filed this 8-K on March 2, 2020, reporting on events of February 26, 2020.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
|
||
|
(Address of principal executive offices, including zip code) |
||
Registrant’s Telephone Number, Including Area Code:
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the annual meeting of stockholders held on February 26, 2020, Enanta’s stockholders voted on the following proposals, each of which is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on January 17, 2020.
Proposal No. 1: To Elect Two Class I Directors to Serve Until the 2023 Annual Meeting of Stockholders or until their respective successors are elected and qualified.
The stockholders re-elected the following individuals as Class I directors of the Company:
|
Name of Director Nominee |
|
Votes For |
|
|
Votes Withheld |
|
|
Broker Non-Votes |
|
|||
|
Bruce L.A. Carter, Ph.D. |
|
|
15,986,607 |
|
|
|
258,954 |
|
|
|
977,102 |
|
|
Jay R. Luly, Ph.D. |
|
|
16,194,985 |
|
|
|
50,576 |
|
|
|
977,102 |
|
Proposal No. 2: To Approve, on an Advisory Basis, the Compensation Paid to the Company’s Named Executive Officers.
The stockholders approved the advisory vote on executive compensation, or a “say-on-pay” vote.
|
Votes For |
|
|
Votes Against |
|
|
Abstain |
|
|
Broker Non-Votes |
|
||||
|
|
16,020,567 |
|
|
|
210,024 |
|
|
|
14,970 |
|
|
|
977,102 |
|
Proposal No. 3: To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta’s Independent Registered Public Accounting Firm for the 2020 Fiscal Year.
The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2020.
|
Votes For |
|
|
Votes Against |
|
|
Abstain |
|
|
Broker Non-Votes |
|||
|
|
16,925,959 |
|
|
|
283,266 |
|
|
|
13,438 |
|
|
0 |
|
|
|
|
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
ENANTA PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
Date: March 2, 2020 |
|
By: |
/s/ Paul J. Mellett |
|
|
|
|
Paul J. Mellett |
|
|
|
|
Senior Vice President, Finance and Administration and Chief Financial Officer |
2